Norway
3.9researchednon-EUExceptional demand behind a closed door. Roughly NOK 2.6bn is spent out of pocket across 5.6m people, several times the Swedish figure per head, and the only reimbursement pathway is a narrow subgroup the Storting still has not funded. But inbound cross-border supply is flatly banned, more than 90 per cent of pharmacies sit in three chains, and DMP has now issued a stop order against a weight-loss telehealth operator. Our earlier score of 4.3 was too generous and has been marked down.
- Population
- 5.6m
- Currency
- NOK
- Region
- Nordic Europe
- Updated
- 2026-08-24
The six axes
Five is always better for an operator. Hover a label for the question it answers.
How it works here
Ownership, and the EEA prescription rule worth knowing [1][2]
Apotekloven (LOV-2000-06-02-39) opened pharmacy ownership to corporate and foreign investors from 1 March 2001, subject to a suitability and financial-capacity test. By 2022 Apotek 1, Vitusapotek and Boots held the large majority of roughly 940 pharmacies.
The rule worth building around is Helsedirektoratet §9-5: a Norwegian pharmacy may fill a prescription issued by any EEA-authorised prescriber, provided the medicine holds Norwegian marketing authorisation and the prescription is legible and authentic. Oral and verbal prescriptions are excluded. That is a genuinely useful cross-border mechanic, and it is why a Swedish-doctor model can plausibly reach Norwegian patients.
Reimbursement: assessed, not funded [1][2]
On 19 to 20 November 2025 DMP published a positive cost-effectiveness assessment of Wegovy after a new price offer from Novo Nordisk, for patients with BMI 35 or above plus at least two weight-related comorbidities. That is well short of the full label.
As of August 2026 there is still no Storting funding decision. Projected cost exceeds 100m NOK a year, so it must pass the Ministry of Health and then a budget appropriation, and DMP states plainly that a positive methodology assessment is not a reimbursement decision. Wegovy was refused blå resept on 19 January 2023 and Saxenda individual support ended as a main rule on 1 February 2023.
Who actually prescribes, and who does not [1][2][3]
Two widely assumed operators turned out not to prescribe at all. Kry.no discontinued its weight-loss programme, and its own page says so; only general lifestyle advice remains on a 365 NOK video consult. Klarovel states explicitly that it does not sell, distribute or prescribe. It is a questionnaire-driven guidance platform that refers users to licensed doctors.
What does prescribe: Dr Dropin (1,295 NOK digital initial, 1,695 NOK in clinic, 795 NOK follow-up, with dedicated vektleger), Helseresepten (995 to 2,695 NOK monthly tiers), and VektFRI (499 NOK monthly membership with a mandatory video consultation, medication billed separately). FagerCare runs a questionnaire-first flow with Swedish-licensed doctors at 49 to 99 euros a month, though Norwegian coverage was not confirmed.
Prices, and a fast-moving counterfeit problem [1][2]
Official pharmacy prices from Felleskatalogen: Wegovy 1,748.20 NOK for 0.25 to 1mg, 2,605.00 NOK at 1.7mg, 3,205.40 NOK at 2.4mg per four-week pen. Ozempic 1,223.60 NOK at 0.25 and 0.5mg. Mounjaro runs roughly 2,371 to 5,754 NOK per four-week pack by dose.
Norwegian Customs reported over 6,200 seizures of GLP-1 products in 2025, against fewer than ten across 2023 and 2024 combined. The Health Director called the trend concerning in April 2026, and a seizure of counterfeit Mounjaro in Swedish packaging sold through illegal sites was reported separately. That is the sharpest enforcement signal in the Nordics right now.
The pill [1]
Neither oral product is available. CHMP recommended the oral Wegovy tablet on 22 May 2026 and DMP published the news itself, but EEA incorporation of the European Commission decision had not produced a Norwegian launch as of this research. Orforglipron holds a UK MHRA authorisation only, which does not reach the EEA.
Who is already there
| Name | Model | Price |
|---|---|---|
| Dr.Dropin | Clinic chain, in-person and digital, dedicated vektleger. Names zero molecules. | 1,295 NOK digital initial, 1,695 in clinic, 795 follow-up |
| Helseresepten | Tiered subscription with four-weekly video. Subject of a DMP stop order in June 2026. | 995 to 2,695 NOK/month |
| VektFRI (Legedrift AS) | Mandatory video consultation. The only visibly profitable model in the Nordics. | 499 NOK/month, medicine separate |
| Dr Dropin | In-clinic and digital, with dedicated vektleger | 1,295 NOK digital initial, 1,695 NOK in clinic, 795 NOK follow-up |
| Helseresepten | Tiered subscription, multidisciplinary team, four-weekly video | 995 to 2,695 NOK/month |
| VektFRI | Mandatory video consultation plus an ongoing portal | 499 NOK/month membership, medication separate |
| FagerCare | Questionnaire-first, doctor call optional, Swedish-licensed doctors | 49 to 99 euros/month, medication extra |
| Kry.no | Weight-loss programme discontinued. General video consults only | 365 NOK per consult |
| Klarovel | Information and protocol guidance only. Explicitly does not prescribe or dispense | n/a |
Routes in, and walls
What works viable
- Obtain an apotekkonsesjon from DMP without being a pharmacist, subject to the suitability test.
- Or run a telehealth-only clinic with Norwegian-authorised physicians prescribing via e-resept, fulfilled through any DMP-registered pharmacy netthandel channel.
- Use §9-5 deliberately. An EEA-authorised prescriber can write a prescription a Norwegian pharmacy will fill, which opens a real cross-border model.
What does not blocked
- Dispensing a medicine without Norwegian marketing authorisation.
- Accepting oral or verbal prescriptions for fulfilment.
- Treating Kry or Klarovel as competitors in this category. Neither prescribes GLP-1s.
How to make it work
The recommended entry path for a non-pharmacist operator running an own brand with a partner pharmacy. Read it against the six axes above, not instead of them.
Wait. If you go, go as a Norwegian-licensed telehealth clinic prescribing into e-resept, and do not plan any cross-border supply.
Demand is exceptional, roughly NOK 2.6bn out of pocket across 5.6m people, several times Sweden per head. But three things narrowed since we first scored it. Inbound cross-border supply is flatly banned, so the model that works in Germany simply does not exist here. Ownership is deregulated in law but over 90 per cent of pharmacies sit in three chains and consolidation continues. And DMP issued a stop order against a weight-loss telehealth operator in June 2026, so the advertising rule is live rather than theoretical. Our score came down from 4.3 to 3.9.
- Read the Helseresepten decision before writing a word of copyCase 25/22387-8. It holds that a commercial interest in prescribing establishes advertising intent, and it rejected a healthcare-professional gate not in principle but because the disclaimer was not credible against patient-facing copy and used the wrong statutory definition. That is an engineering fix, not a closed door.
- Assume no inbound supplyDMP says postal consignments of medicines from abroad are not permitted, explicitly including where the patient holds a Norwegian prescription. EEA e-prescriptions cannot pass Reseptformidleren.
- Use Norwegian-authorised prescribers and e-reseptThe section 9-5 route for EEA prescribers survives only for prescriptions issued in writing, which is not a business.
- Do not assume you can connect your own front endThe e-resept EPJ whitelist is closed. Budget for Norsk Helsenett, and note the 5.9x price cliff at NOK 40m turnover.
- Watch the StortingDMP recommended Wegovy for blå resept in November 2025 for BMI 35 plus two comorbidities, over 70,000 people, and it awaits an appropriation. Reimbursement arriving would change the cash-pay thesis substantially.
The advertising rule combined with the supply ban. You cannot import, you cannot easily advertise, and the pharmacy layer is an oligopoly. Norway is a demand market you may end up serving badly.
Higher than it looks. Treat as a second-wave market behind Sweden.
What has happened
What we could not establish
Kept visible on purpose. These are the gaps a decision would have to close.
- Has the Storting funded the narrow Wegovy subgroup, and in which budget?
- What is the verified full-year 2025 NOK figure for weight-loss medicine sales? Press cited 2.2bn and 2.5bn but only as headlines.
- Does FagerCare’s Swedish-doctor model actually serve Norwegian patients?
- Has DMP taken any advertising action against a telehealth operator rather than a pharmacy?
Sources
Every non-obvious claim above links here. Confidence tags are applied strictly.
Read next
Yazen
The only operator in this atlas that never touches the drug, and the only one that runs eight countries out of a single Swedish company under Swedish law.
companyKry / Livi
The largest Nordic general telehealth platform, operating as Livi outside Sweden, a distribution channel more than a GLP-1 specialist.
companyHelseresepten
The only weight-loss telehealth operator in the Nordics with a published regulator stop order against it, and the decision is the clearest statement of the advertising rule anywhere in this atlas.
companyDr.Dropin
By far the largest player in Norway by revenue, a physical and digital clinic chain rather than a weight-loss brand, and it names no molecule at all.
companyVektFRI
The only visibly profitable weight-loss model in the Nordics, at a 43 per cent operating margin, and it runs the opposite compliance posture to everyone else in Norway.
company